Cathie Wood ARK ETF Buys Recursion Pharmaceuticals and CRISPR Therapeutics Shares

TLDR

• ARK Invest bought 1.25M shares of Recursion Pharmaceuticals for $4.33M
• ARK added 37,075 CRISPR Therapeutics shares worth $1.97M
• PagerDuty was the biggest sell at $3.89M for 566,650 shares
• ARK also cut positions in Teradyne, DraftKings, Twist Bioscience, and Salesforce
• Trades signal a rotation from tech into biotech

Cathie Wood’s ARK Invest disclosed its daily trades for February 18, 2026, showing a clear move out of tech stocks and into biotech.

The filings cover ARK’s actively managed ETFs, which are required to publish every buy and sell the next day.

ARK made seven trades in total. Two were purchases, both in biotech. Five were sales, spread across tech, software, and consumer names.

ARK’s Biggest Buys

The largest single trade of the day was a purchase of 1,251,270 shares of Recursion Pharmaceuticals for around $4.33 million. ARK has been adding to this position for several consecutive sessions.

Recursion Pharmaceuticals, Inc., RXRX

Recursion uses artificial intelligence to speed up drug discovery. The stock rose about 2% on February 18.

ARK also bought 37,075 shares of CRISPR Therapeutics for roughly $1.97 million. That purchase extended a week-long accumulation in the gene-editing biotech company.

CRISPR Therapeutics ended the day up around 0.66%.

What ARK Sold

The biggest sell was PagerDuty, where ARK offloaded 566,650 shares for about $3.89 million. ARK has been reducing its PagerDuty stake across multiple recent sessions.

ARK sold 11,366 shares of Teradyne for roughly $3.47 million. The semiconductor equipment maker had already seen its stock rise around 3% following earnings earlier in February, but ARK continued trimming.

DraftKings saw ARK cut 103,218 shares worth about $2.33 million. The online sports betting platform has been on ARK’s sell list for several days running.

Twist Bioscience was sold again, with ARK exiting 18,162 shares for nearly $960,000. That followed a larger sale of 119,374 shares worth $6.31 million on February 17. Twist had moved higher after announcing a licensing deal with Invenra, gaining co-exclusive rights to a bispecific antibody platform.

ARK also trimmed 7,662 shares of Salesforce for around $1.41 million. Salesforce closed about 2% higher at $187.79 on the same day.

The Bigger Picture

Across the seven trades, ARK spent roughly $6.3 million buying biotech and raised around $12 million from selling tech and consumer names.

The disclosures are factual and based on ARK’s required daily fund filings for February 18, 2026.

Recursion Pharmaceuticals and CRISPR Therapeutics are now among the positions ARK has been actively growing over the past week.

The post Cathie Wood ARK ETF Buys Recursion Pharmaceuticals and CRISPR Therapeutics Shares appeared first on Blockonomi.